Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · October 22, 2022

Safety and Efficacy of Dupilumab in Children Aged Between 6 Months and 6 Years With Uncontrolled Atopic Dermatitis

The Lancet


Additional Info

The Lancet
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2022 Sep 17;400(10356)908-919, AS Paller, EL Simpson, EC Siegfried, MJ Cork, A Wollenberg, PD Arkwright, W Soong, ME Gonzalez, LC Schneider, R Sidbury, B Lockshin, S Meltzer, Z Wang, LP Mannent, N Amin, Y Sun, E Laws, B Akinlade, M Dillon, MP Kosloski, MA Kamal, A Dubost-Brama, N Patel, DM Weinreich, GD Yancopoulos, JT O'Malley, A Bansal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading